Long-Term Survivors in Myelodysplastic Syndromes: Clinical and Biological Characteristics
article
OA: closed
CC0
Abstract
Twenty-eight of 285 patients (9.8%) with primary myelodysplastic syndrome (MDS) survived more than 5 yr (long-term survivors). There were 21 females and 7 males, median age 60 yr (range 18-84 yr). None had circulating blasts, and 14 had refractory anemia (RA), 8 RA with ringed sideroblasts (RARS) and 6 RA with excess of blasts (RAEB). Thirty-seven percent of the 27 patients who were karyotyped had an abnormal clone, but none of them had -7/7q- or complex cytogenetic abnormalities. Only one of the 13 patients tested had abnormal (i.e., "leukemic") in vitro growth of GM progenitors. During 5 yr following the diagnosis, none of the 28 patients progressed to AML. Two patients with an initial diagnosis of RA showed progression to RAEB and CMML. After 5 yr, 23 of the 28 long-term survivors had stable disease (follow-up period ranged from 64 to 216 mo). One patient progressed to AML (113 mo after diagnosis) and another to RAEBT (80 mo after diagnosis). Eight asymptomatic patients were not treated and 12 patients received only supportive therapy. Except for 6 of 8 treated patients who responded to low-dose Ara-C, danazol, androgens, or immunosuppressive treatment, prolonged survival seemed to result mainly from the natural course of the disease. Except for Valensia score (p=0.033), other scoring systems (Bournemouth, Dusseldorf, Lille, and IPSS score) proved of relatively limited value in differentiating between intermediate (2-5 yr) and long-term survivors.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
References (21)
- doi:10.1385/mo:19:4:249 via openalex
- doi:10.1007/978-1-4612-4380-9_25 via openalex
- doi:10.1111/j.1365-2141.1988.tb04173.x via openalex
- doi:10.1016/0145-2126(90)90133-t via openalex
- doi:10.1111/j.1365-2141.1982.tb02771.x via openalex
- doi:10.1182/blood.v74.1.395.395 via openalex
- doi:10.1111/j.1365-2141.1982.tb08475.x via openalex
- doi:10.1182/blood.v89.6.2079 via openalex
- doi:10.1016/0145-2126(93)90106-u via openalex
- doi:10.1016/0165-4608(94)90007-8 via openalex
- doi:10.1111/j.1600-0609.1994.tb01320.x via openalex
- doi:10.1016/0145-2126(92)90089-p via openalex
- doi:10.1111/j.1365-2141.1985.tb07329.x via openalex
- doi:10.3109/10428199409049656 via openalex
- doi:10.1111/j.1365-2141.1984.tb06079.x via openalex
- doi:10.1016/s0950-3536(96)80042-4 via openalex
- doi:10.1182/blood.v79.1.198.198 via openalex
- W2225322761 via openalex
- W2262570289 via openalex
- doi:10.1016/0145-2126(92)90090-t via openalex
- doi:10.1016/0145-2126(92)90156-2 via openalex
Source provenance
- openalex
- last seen: 2026-05-11T05:50:48.314143+00:00
- unpaywall
- last seen: 2026-08-10T06:43:36.850308+00:00
License: CC0
· commercial use OK